摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-二羟基黄酮 | 38183-04-9

中文名称
6,7-二羟基黄酮
中文别名
——
英文名称
6,7-dihydroxyflavone
英文别名
6,7-Dihydroxyflavon;6,7-dihydroxy-2-phenyl-4H-chromen-4-one;6,7-dihydroxy-2-phenylchromen-4-one
6,7-二羟基黄酮化学式
CAS
38183-04-9
化学式
C15H10O4
mdl
——
分子量
254.242
InChiKey
GSAOUZGPXSGVRS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    251-254°C
  • 沸点:
    521.6±50.0 °C(Predicted)
  • 密度:
    1.443±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66.8
  • 氢给体数:
    2
  • 氢受体数:
    4

ADMET

代谢
6,7-二羟基黄酮已知的人类代谢物包括(2S,3S,4S,5R)-3,4,5-三羟基-6-(6-羟基-4-酮-2-苯基色烯-7-基)氧杂环己烷-2-羧酸
6,7-Dihydroxyflavone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(6-hydroxy-4-oxo-2-phenylchromen-7-yl)oxyoxane-2-carboxylic acid.
来源:NORMAN Suspect List Exchange

安全信息

  • 海关编码:
    2914400090

SDS

SDS:f5e3723deb3eb0de0c9c6d05d7d5124b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    256.色酮类的合成实验。第八部分:邻羟基,2:5-二羟基和2:4:5-三羟基苯乙酮的衍生物
    摘要:
    DOI:
    10.1039/jr9330001073
  • 作为产物:
    描述:
    黄酮 在 cytochromes P450 in human liver microsomes 作用下, 生成 6,7-二羟基黄酮
    参考文献:
    名称:
    黄酮类苷元代谢中细胞色素P450介导的O-去甲基化和芳羟基化的表征
    摘要:
    代谢酶中最重要的一组之一是细胞色素P450超家族。这些酶在催化多样性方面很重要
    DOI:
    10.5562/cca3528
点击查看最新优质反应信息

文献信息

  • Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches
    作者:Baojian Wu、Xiaoqiang Wang、Shuxing Zhang、Ming Hu
    DOI:10.1007/s11095-012-0666-z
    日期:2012.6
    Catalytic selectivity of human UGT1A9, an important membrane-bound enzyme catalyzing glucuronidation of xenobiotics, was determined experimentally using 145 phenolics and analyzed by 3D-QSAR methods. Catalytic efficiency of UGT1A9 was determined by kinetic profiling. Quantitative structure activity relationships were analyzed using CoMFA and CoMSIA techniques. Molecular alignment of substrate structures was made by superimposing the glucuronidation site and its adjacent aromatic ring to achieve maximal steric overlap. For a substrate with multiple active glucuronidation sites, each site was considered a separate substrate. 3D-QSAR analyses produced statistically reliable models with good predictive power (CoMFA: q2 = 0.548, r2 = 0.949, r pred 2  = 0.775; CoMSIA: q2 = 0.579, r2 = 0.876, r pred 2  = 0.700). Contour coefficient maps were applied to elucidate structural features among substrates that are responsible for selectivity differences. Contour coefficient maps were overlaid in the catalytic pocket of a homology model of UGT1A9, enabling identification of the UGT1A9 catalytic pocket with a high degree of confidence. CoMFA/CoMSIA models can predict substrate selectivity and in vitro clearance of UGT1A9. Our findings also provide a possible molecular basis for understanding UGT1A9 functions and substrate selectivity.
    通过实验使用145种酚类化合物,并通过3D-QSAR方法分析,确定了人UGT1A9的催化选择性。UGT1A9是一种重要的膜结合酶,催化外源性物质的葡糖醛酸化反应。通过动力学分析确定了UGT1A9的催化效率。使用CoMFA和CoMSIA技术分析了定量结构活性关系。通过将葡糖醛酸化位点及其相邻的芳香环重叠,实现了底物结构的最大立体重叠。对于具有多个活性葡糖醛酸化位点的底物,每个位点被视为单独的底物。3D-QSAR分析产生了统计上可靠的模型,具有良好的预测能力(CoMFA:q2=0.548,r2=0.949,r pred 2=0.775;CoMSIA:q2=0.579,r2=0.876,r pred 2=0.700)。通过轮廓系数图阐明了底物中负责选择性差异的结构特征。将轮廓系数图叠加在UGT1A9的同源模型的催化口袋中,能够高度自信地识别UGT1A9的催化口袋。CoMFA/CoMSIA模型可以预测底物的选择性和UGT1A9的体外清除率。我们的发现还提供了理解UGT1A9功能和底物选择性的可能分子基础。
  • Structure-activity Relationships for α-Glucosidase Inhibition of Baicalein, 5,6,7-Trihydroxyflavone: the Effect of A-Ring Substitution
    作者:Hong GAO、Tetsuo NISHIOKA、Jun Kawabata、Takanori KASAI
    DOI:10.1271/bbb.68.369
    日期:2004.1
    In order to estimate the effects of the A-ring hydroxyl group of baicalein (5,6,7-trihydroxyflavone, 1) on rat intestinal α-glucosidase inhibition, flavone, monohydroxyflavones, dihydroxyflavones, and methylated derivatives of 5,6,7-trihydroxyflavone were used for the structure-activity relationship (SAR) study. The importance of the 6-hydroxyl group of baicalein was validated for an exertion of the activity. And also, the tested flavones which lacked a hydroxyl substituent on any of positions 5, 6, or 7, showed no activity. Hence, the 5,6,7-trihydroxyflavone structure was concluded to be crucial for the potent inhibitory activity. In addition, an introduction of electron-withdrawing or electron-donating groups at position 8 of baicalein led to a dramatic decrease for activity, except for 8-fluoro-5,6,7-trihydroxyflavone, which carried a less bulky substituent on position 8. Hence, this result suggested that a sterically bulky substituent on C-8 of baicalein was detrimental for the activity regardless of its electronic nature. Through examining the inhibitory mechanism of baicalein against rat intestinal α-glucosidase, it was suggested to be a mixed type inhibition.
    为了估计黄芩(5,6,7-三羟基黄酮,1)的A环羟基对大鼠肠α-葡萄糖苷酶抑制的影响,采用了黄酮、单羟基黄酮、二羟基黄酮及5,6,7-三羟基黄酮的甲基化衍生物进行结构-活性关系(SAR)研究。验证了黄芩的6-羟基对该活性的发挥的重要性。此外,测试的黄酮若在5、6或7位上缺乏羟基取代基,则显示无活性。因此,得出5,6,7-三羟基黄酮结构对强抑制活性至关重要的结论。此外,在黄芩的8位引入电子吸引或电子给体基团会使活性急剧降低,唯独8--5,6,7-三羟基黄酮因其在8位上带有体积较小的取代基而例外。因此,该结果表明,黄芩C-8上的空间庞大取代基无论其电子性质如何,对活性都是不利的。通过研究黄芩对大鼠肠α-葡萄糖苷酶的抑制机制,建议其为混合型抑制。
  • New Methods for the Synthesis of Spirocyclic Cephalosporin Analogues
    作者:Alan Zhao、Louise Horsfall、Alison Hulme
    DOI:10.3390/molecules26196035
    日期:——
    Spiro compounds provide attractive targets in drug discovery due to their inherent three-dimensional structures, which enhance protein interactions, aid solubility and facilitate molecular modelling. However, synthetic methodology for the spiro-functionalisation of important classes of penicillin and cephalosporin β-lactam antibiotics is comparatively limited. We report a novel method for the generation
    由于其固有的三维结构,螺环化合物在药物发现中提供了有吸引力的靶标,可增强蛋白质相互作用,有助于溶解度并促进分子建模。然而,重要类别青霉素头孢菌素β-内酰胺抗生素的螺功能化的合成方法相对有限。我们报告了一种通过二氢噻嗪环的迈克尔型加成生成螺头孢菌素化合物的新方法。一系列儿茶酚的偶联是在弱碱性条件(K 2 CO 3 、DMF)下实现的,以中等至良好的产率(28−65%)立体选择性地形成螺头孢菌素(dr 14:1 至 8:1) 。
  • Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases
    申请人:Gong Qiang Bang
    公开号:US20050049206A1
    公开(公告)日:2005-03-03
    In this invention, we describe a group of flavonoids and flavonoid-containing extracts that have pharmaceutical properties which are useful in the medicinal therapy of fibrotic diseases for the treatment or reparation and prevention of fibrotic lesional tissues. Representative flavonoids and flavonoid-containing extracts have the active compositions of the below formula. Those compositions can be extracted and purified from the botanicals, including Scutellaria baicalensis Georgi, Scutellaria scordifolia Fisch,Oroxylum indicum(L.) Vent, Plantago major L. The compositions of the invention are novel as an anti-fibrotic drugs, as agents for treating fibrosis.
    在这项发明中,我们描述了一组黄酮类化合物和含黄酮类化合物提取物,具有药物特性,可用于治疗纤维化疾病的药物疗法,用于治疗、修复和预防纤维化病变组织。代表性的黄酮类化合物和含黄酮类化合物提取物具有以下公式的活性成分。这些成分可以从植物中提取和纯化,包括黄芩、紫花地丁、橙黄木、车前草等。本发明的成分作为抗纤维化药物和治疗纤维化的药剂是新颖的。
  • Flavonoid Complexes
    申请人:Carola Christophe
    公开号:US20080044364A1
    公开(公告)日:2008-02-21
    The invention relates to compounds of the formula I where R 1 to R 10 may be identical or different and are selected from H, OR 11 , straight-chain or branched C 1 - to C 20 -alkyl groups or hydroxyalkyl groups, straight-chain or branched C 3 - to C 20 -alkenyl groups and/or C 3 - to C 12 -cycloalkenyl groups, where the rings may each also be bridged by —(CH 2 ) n — groups, where n=1 to 3, where all OR 11 , independently of one another, stand for OH, C 1 - to C 20 -alkoxy groups, C 3 - to C 20 -alkenyloxy groups, straight-chain or branched C 1 - to C 20 -hydroxyalkoxy groups and/or C 3 - to C 10 -cycloalkoxy groups and/or C 3 - to C 12 -cycloalkenyloxy groups, where the rings may each also be bridged by —(CH 2 ) n — groups, where n=1 to 3, and/or mono- and/or oligoglycosyl radicals, CD stands for a cyclodextrin molecule, o stands for the number 1 and p stands for a number from the range 0.5 to 50, with the proviso that at least 2 radicals from R 1 to R 7 stand for OH and that at least 1 pair of adjacent —OH groups is present in the molecule.
    本发明涉及公式I的化合物,其中R1至R10可以相同或不同,选择自H、OR11、直链或支链C1至C20烷基或羟基烷基、直链或支链C3至C20烯基和/或C3至C12环烯基,其中环也可以由—(CH2)n—基桥接,其中n=1至3,其中所有的OR11独立地代表OH、C1至C20烷氧基、C3至C20烯氧基、直链或支链C1至C20羟基烷氧基和/或C3至C10环烷氧基和/或C3至C12环烯氧基,其中环也可以由—( )n—基桥接,其中n=1至3,并/或单糖和/或寡糖基团,CD代表环糊精分子,o代表数字1,p代表范围0.5至50的数字,但至少有2个来自R1至R7的基团代表OH,并且分子中至少存在1对相邻的—OH基团。
查看更多